Entera Bio Ltd (ENTX) is not a good buy for a beginner, long-term investor at this time. The stock is showing bearish technical indicators, poor financial performance, and lacks positive catalysts or strong trading signals to support a buy decision. Additionally, there are no influential trades or recent news to suggest a potential upside.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. The MACD histogram is negative and expanding downward, indicating bearish momentum. RSI is neutral at 31.938, and the stock is trading below the pivot level of 1.34, with key support at 1.169 and resistance at 1.512.

NULL identified. No recent news or significant insider/hedge fund activity. No recent congress trading data.
The company's financials are weak, with a 100% YoY revenue drop in Q3 2025, negative EPS growth (-12.50% YoY), and a net income loss of -$3.2M. Technical indicators are bearish, and options sentiment shows a high put-call ratio, indicating bearish sentiment.
In Q3 2025, revenue dropped to $0 (-100% YoY), net income improved slightly to -$3.2M (+5.93% YoY), EPS dropped to -0.07 (-12.50% YoY), and gross margin remained at 0%. Overall, the financial performance is weak with no signs of growth.
No recent analyst ratings or price target changes available.
